Adalimumab for Crohn's disease: Long-term sustained benefit in a population-based cohort of 438 patients

C.P. Peters, E.J. Eshuis, F.M. Toxopeus, M.E. Hellemons, J.M. Jansen, G.R.A.M. D'Haens, P. Fockens, P.C.F. Stokkers, H.A.R.E. Tuynman, A.A. van Bodegraven, C.Y. Ponsioen

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)866-875
JournalJournal of Crohn's and Colitis
Volume8
Issue number8
DOIs
Publication statusPublished - 2014

Cite this

Peters, C. P., Eshuis, E. J., Toxopeus, F. M., Hellemons, M. E., Jansen, J. M., D'Haens, G. R. A. M., ... Ponsioen, C. Y. (2014). Adalimumab for Crohn's disease: Long-term sustained benefit in a population-based cohort of 438 patients. Journal of Crohn's and Colitis, 8(8), 866-875. https://doi.org/10.1016/j.crohns.2014.01.012